Skip to main content
Article thumbnail
Location of Repository

Patients’ health literacy in psychotic disorders

By Ghassen Saba, Lila Mékaoui, Marion Leboyer and Franck Schürhoff

Abstract

Compliance and relapse are major issues in the treatment of psychotic disorders. About 50% of subjects with schizophrenia do not comply with treatment and relapse rates of 65% are reported after one year and 80% after two years. Drug treatments are effective against psychotic symptoms, but cannot promote functional recovery or prevent relapses when prescribed alone. The factors influencing compliance include side effects and the patients’ awareness of their illness. Psychosocial interventions, cognitive remediation and psychotherapy have been proposed as adjuvant treatments to increase compliance and to decrease the rate of relapse. Most of these interventions have been shown to increase compliance and to decrease the rate of relapse, but the most robust results have been achieved with cognitive behavioral therapy

Topics: Original Research
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2655084
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2004). A pilot study of barrier to medication adherence in schizophrenia.
    2. (2005). A pilot study of functional cognitive behavioural therapy (FCBT) for schizophrenia. Schizophrenia Research,
    3. (2005). A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in acute patients with schizophrenia: outcome at 24 months. Acta Psychiatrica Scandinavica,
    4. (2000). A randomized controlled trial of cognitive behavioural therapy for persistant symptoms in schizophrenia resistant to medication.
    5. (2005). A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder.
    6. (1990). Adherence to antipsychotic medications.
    7. (2004). Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.
    8. (2005). Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
    9. (1994). Awareness of illness in schizophrenia and schizoaffective and mood disorders.
    10. (1997). Characterizing quality of life among patients with chronic mental illness: a critical examination of the selfreport methodology.
    11. (1993). Coercion and “voluntary” admission: an examination of psychiatric patients’ views. Behav Sci Law,
    12. (2006). Cognitive behaviour therapy for schizophrenia.
    13. (2005). Cognitive behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication.
    14. (2004). Cognitive behavioural therapy in fi rst-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial.
    15. (2004). Cognitive enhancement therapy in schizophrenia: Effects of a 2-year randomized trial on cognition and behaviour.
    16. (1999). Cognitive functioning in schizophrenia: implication for psychiatric rehabilitation. Schizophrenia Bulletin,
    17. (2003). Cognitive mechanisms, psychosocial functioning, and neurocognitive rehabilitation in schizophrenia.
    18. (2003). Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia.
    19. (2004). Cognitive therapy for command hallucinations: randomised controlled trial.
    20. (2003). Cognitive therapy for schizophrenia: a preliminary randomised controlled trial. Schizophrenia Research,
    21. (2004). Compliance in schizophrenia: psychopathology, side effects, and patients attitudes toward the illness and medication.
    22. (1985). Compliance issues in outpatients treatment.
    23. (1996). Compliance therapy in psychotic patients: randomised controlled trial.
    24. (1994). Compliance, quality assurance and standards for relapse prevention in schizophrenia.
    25. (2000). De quelles informations les patients souffrant de schizophrénie disposent-ils sur leur maladie et leurs traitements? Encéphale,
    26. (2000). Depot fl upenthixol decanoate for schizophrenia or similar psychotic disorders. The Cochrane Library 4.
    27. (1997). Determinants of medication compliance in schizophrenia: empirical and clinical fi ndings. Schizophrenia Bulletin,
    28. (2002). Effectiveness of a brief cognitive behavioural therapy intervention in the treatment of schizophrenia.
    29. (1997). Effi cacy of 12-week trial of olanzapine in treatment of refractory schizophrenia or schizoaffective disorders.
    30. (2005). Housing, social support and people with schizophrenia: a grounded theory study. Ment Health Nurs,
    31. (2005). Identifi cation and treatment of patients with nicotine problems in routine clinical psychiatry practice.
    32. (2001). Impact of an early psychosis program on substance use.
    33. (2004). Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
    34. (2002). Indicators of medication compliance in first-episode psychosis.
    35. (2004). Insight and recovery from psychosis in chronic schizophrenia and schizoaffective disorder patients.
    36. (2000). Insight and suicidality in schizophrenia: a replication study.
    37. (2005). Insight into schizophrenia: the effect of cognitive behavioural therapy on the components of insight and association with sociodemographics data on a previously published randomised trial. Schizophrenia Research,
    38. (1997). Insight, neurocognitive function and symptoms clusters in chronic schizophrenia.
    39. (2004). Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr Serv,
    40. (2004). Neurocognitive correlates of therapeutic alliance in schizophrenia.
    41. (1991). Neuroleptic non-compliance in schizophrenia,
    42. (2004). North Wales randomised controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: outcomes at 6 and 12 months.
    43. (1999). Predictors of relapse following response from a fi rst episode of schizophrenia or schizoaffective disorder.
    44. (2005). Predictors of remediation success on a trained memory task.
    45. (2002). Prevalence risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature.
    46. (2002). Psychological treatment in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation.
    47. (2005). Psychosocial treatment for fi rst-episode psychosis: A research update.
    48. (2000). Quality of life in fi rst admitted schizophrenia patients: a follow up study.
    49. (2002). Randomised controlled trial of cognitive behavioural therapy in early schizophrenia: acute-phase outcome.
    50. (1998). Randomized controlled trial of intensive cognitive therapy for patients with chronic schizophrenia.
    51. (1996). Relationship between insight, educational background and cognition in schizophrenia.
    52. (2003). Relationships between insight and medication adherence in subjects with psychosis. L’Encéphale,
    53. (2000). Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane review). The Cochrane Library 4.
    54. (2003). Schizophrenic patients’ subjective reasons for compliance and non-compliance with neuroleptic treatment.
    55. (2001). Social functioning in fi rst- and multiepisode schizophrenia.
    56. (2003). Social outcome in early psychosis.
    57. (2000). Sources of coercitive behaviours in psychiatric admissions.
    58. (2004). Suicidal behaviour in early Psychosis. Acta Psychiatrica Scandinavica,
    59. (2003). Symptom outcome one year after admission to an early psychosis program.
    60. (2003). Tayside-Fife clinical trial of cognitive-behavioural therapy for medication resistant psychotic symptoms. Results to 3-months follow-up.
    61. (2005). The effect of cognitive behavioural treatment on positive symptoms of schizophrenia spectrum disorders: A meta-analysis. Schizophrenia Research,
    62. (1999). The effects of neurocognitive remediation on executive processing in patients with schizophrenia.
    63. (2002). The effects of novel antipsychotics on glucose and lipid levels.
    64. (2006). The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev,
    65. (2004). The quest for well-being: a qualitative study of the experience of taking antipsychotic medication. Psychol Psychother,
    66. (1989). The role of social relationship in the course of fi rst-episode and affective psychosis.
    67. (1997). Three year trial of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates.
    68. (1997). Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates.
    69. (1996). Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.